House subcommittee proposes $257M increase for FDA in FY2022
Regulatory NewsMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyCombination products/companion diagnosticsDiagnostics/IVDsMedical DevicesPharmaceuticalsRegulatory NewsMichael MezherBiologics/ biosimilars/ vaccinesBiotechnologyCombination products/companion diagnosticsDiagnostics/IVDsMedical DevicesPharmaceuticals